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Abstract
Longevity is increasing and the population of older adults is growing. The
biology of aging is conducive to cardiovascular disease (CVD), such that
prevalence of coronary artery disease, heart failure, valvular heart disease,
arrhythmia and other disorders are increasing as more adults survive into old
age.  Furthermore, CVD in older adults is distinctive, with management issues
predictably complicated by multimorbidity, polypharmacy, frailty and other
complexities of care that increase management risks (e.g., bleeding, falls, and
rehospitalization) and uncertainty of outcomes.  In this review, state-of-the-art
advances in heart failure, acute coronary syndromes, transcatheter aortic valve
replacement, atrial fibrillation, amyloidosis, and CVD prevention are discussed. 
Conceptual benefits of treatments are considered in relation to the challenges
and ambiguities inherent in their application to older patients.
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Introduction
The unprecedented growth of the elderly population throughout 
the world is evolving as a challenge for clinicians, governments, 
and health policy guidance. Older adults differ from those typically 
studied in clinical trials, efficacy and outcomes of care often remain 
ambiguous for older patients, and growing healthcare cost burdens 
for older adults are a related concern. In this review, we highlight 
some key advances associated with improved outcomes that have 
recently occurred in the management of older adults with cardio-
vascular disease.
Demographics
The population of older adults is growing rapidly, particularly as 
longevity is also increasing. In the United States, the population 
aged 65 and over is projected to be 83.7 million by 2050, almost 
double the 43.1 million in 20121. The numbers of those who are very 
old (≥85 years) is growing the most rapidly. On a global level, the 
population ≥85 years is projected to increase 151% between 2005 
and 2030, compared to the increase of only 104% in the population 
aged ≥65 years and only 21% for the population under 652. Similar 
growth of elderly populations is occurring in both developed and 
developing countries. Between 2012 and 2030, the percentages of 
adults older than 65 years are expected to increase 33.2% in Japan, 
27.9% in Germany, and 25.5% in Italy3. In China, the world’s most 
populous country of 1.4 billion, the subgroup aged ≥65 years is 
expected to increase by 17.2% by 2030 and 26.8% by 2050, or 
stated as numbers, 350 million Chinese (a magnitude that is greater 
than the total US population) will soon be senior adults3.
Distinctive implications of aging
Geriatric features often transform healthcare challenges and are 
important concerns for clinical decision-making. Whereas cardio-
vascular management standards are fundamentally oriented to spe-
cific cardiac diseases, older adults typically present with multiple 
disease states occurring concurrently such that presentation and 
management of the cardiac issues are inherently more complex4. 
In some cases, multimorbid disease states lead to compounding 
instabilities (e.g. heart failure [HF] and renal failure). In other 
cases, multimorbidities give rise to new disease states (e.g. HF and 
preserved ejection fraction [HFpEF] arising from the substrate of 
metabolic disease and inflammation)5. Non-cardiac comorbid con-
ditions also underlie much of the morbidity and rehospitalizations 
associated with HF, particularly HFpEF6. Geriatric syndromes are 
part of multimorbidity; frailty, sarcopenia, cognitive decline, and 
other age-related dimensions of health fundamentally compound 
multimorbidity management complexities of cardiac conditions7. 
These insights highlight the importance of a holistic approach in 
relation to HF as well as other cardiovascular diseases (CVDs) 
and call attention to the wide range of idiosyncratic capacities, 
vulnerabilities, and therapeutic objectives that typically distinguish 
one older cardiac patient from another. Similarly, typical cardiac 
medications (e.g. angiotensin-converting enzyme [ACE] inhibitors) 
must be regarded not only in terms of their evidence-based car-
diac benefits but also in respect to the iatrogenesis they more easily 
(even predictably) provoke among older adults (e.g. syncope and 
falls) in the context of hypotension, balance or vision impairment, 
sleep deprivation, alcohol use, and other common conditions in an 
older patient population8.
Heart failure
Therapeutic options for the management of HF in older adults 
include medications, devices, and behavioral interventions. The 
PARADIGM-HF trial randomized 8442 patients with sympto-
matic HF and a left ventricular ejection fraction ≤40% to the ACE 
inhibitor enalapril or to the combination of the angiotensin-receptor 
blocker valsartan and the neprilysin inhibitor sacubitril9. Compared 
to enalapril, valsartan/sacubitril was associated with significant 
reductions in cardiovascular death or hospitalization for HF, as well as 
all-cause mortality, cardiovascular mortality, HF hospitalizations, 
and HF-related symptoms. Patients ≥65 years and those ≥75 years 
derived similar benefits from combination therapy, as did younger 
patients. Based on these findings, it is anticipated that valsartan/
sacubitril will be rapidly incorporated into the management of older 
and younger patients with HF and reduced ejection fraction (HFrEF).
In contrast to HFrEF, the treatment of patients with HFpEF, the 
vast majority of whom are elderly, remains problematic. In the 
Treatment of Preserved Cardiac Function Heart Failure With an 
Aldosterone Antagonist (TOPCAT) trial, spironolactone failed 
to reduce the primary outcome of cardiovascular death, aborted 
cardiac arrest, or HF hospitalizations10. Spironolactone reduced HF 
hospitalizations at the expense of increased rates of hyperkalemia 
and elevated serum creatinine. Hence, the role of spironolactone in 
the management of HFpEF remains uncertain.
In the realm of devices, the value of implantable cardioverter-
defibrillators (ICDs) in patients ≥75 years of age remains 
controversial, and selection of older patients for ICDs must be 
individualized11. Mechanical circulatory support (MCS) appears to 
be associated with improved outcomes in carefully selected older 
adults with advanced HF, albeit with increased risk of complica-
tions compared to younger patients12. Pre-morbid frailty is a strong 
predictor of worse outcomes in older adults receiving MCS13.
In the domain of behavioral interventions, there is a need for novel 
approaches that address HF not in isolation, but rather in the con-
text of a complex array of comorbid conditions and heterogeneous 
personal preferences regarding goals of care in order to optimize 
patient-centered outcomes14. In addition, the management of HF in 
long-term care facilities and at the end-of-life now raises special 
considerations to maximize quality of life and reduce suffering15,16.
Acute coronary syndrome
Recent developments in antithrombotic therapy as well as better 
information on frailty and outcomes have benefitted older adults 
with acute coronary syndrome (ACS). A clinical challenge in older 
adults presenting with a myocardial infarction (MI) or undergoing 
percutaneous coronary intervention (PCI) is the indication for mul-
tiple antithrombotic agents (e.g. atrial fibrillation [AF] or valvular 
disease). Triple therapy increases the rate of major bleeding, an out-
come already common among older adults. Two recent European 
registry studies further the understanding of antithrombotic ther-
apy in patients with AF with MI and/or undergoing PCI. Among 
older adults requiring oral anticoagulation presenting with MI or 
undergoing PCI, clopidogrel added to oral anticoagulant therapy 
was as effective as triple therapy (including aspirin) in preventing 
MI/coronary death, ischemic stroke, and bleeding17. In another 
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study, among patients requiring oral anticoagulation undergoing 
PCI (80% ACS, 65% drug-eluting stent and 30% bare metal stent), 
use of clopidogrel without aspirin was also associated with less 
bleeding and no increase in thrombotic events during follow up18. 
A supporting secondary analysis from a large AF clinical trial found 
the oral anticoagulant apixaban had similar beneficial effects on 
stroke, MI, and major bleeding, with or without aspirin, compared 
with warfarin19. Ongoing research is exploring the ability to omit 
aspirin in the setting of an effective oral anticoagulant. These new 
and safer antithrombotic strategies will be an important advance for 
high-risk individuals with coronary artery disease and indications 
for oral anticoagulation.
Older adults are at high risk of adverse outcomes following MI, but 
a Medicare linkage analysis from the CRUSADE Registry provides 
evidence that most mortality occurs early and not in the context of 
rehospitalization. Contrary to expectations, rehospitalization rate did 
not rise substantially with age, in part due to competing mortality. 
Rehospitalizations which did occur were often for non-cardiac 
diagnoses, underscoring the multimorbidity also present in the older 
population with a coronary event20. The TaRgeted platelet Inhibi-
tion to cLarify the Optimal strateGy to medicallY manage Acute 
Coronary Syndromes (TRILOGY ACS) trial, which randomized 
9326 patients with MI planned for medical management to prasug-
rel or clopidogrel, added frailty assessment at baseline for patients 
aged ≥65 years21. The modified Fried score classified 23.0% of the 
older adults in this trial as pre-frail (1–2 items) and 4.7% as frail 
(≥3 items). After adjustment, frailty remained independently asso-
ciated with the composite of cardiovascular death, MI, or stroke: 
pre-frail vs. not-frail, hazard ratio (HR): 1.33; 95% confidence 
interval (CI): 1.15–1.54; p<0.001; frail vs. not-frail, HR: 1.52; 95% 
CI: 1.18–1.98; p=0.002. Frailty among registry populations is 
higher than in clinical trials, so care delivery models should add 
early targeted follow up in older adults after MI, particularly for 
those with multimorbidity or frailty. Future studies will benefit 
from collecting frailty data to allow comparative effectiveness and 
outcomes comparisons across older MI or PCI populations.
Transcatheter aortic valve replacement
Transcatheter aortic valve replacement (TAVR) represents an inno-
vative interventional technology that provides a non-surgical alter-
native for the management of severe aortic stenosis (AS) that has 
particular relevance for the elderly and the very elderly populations. 
The prevalence of AS in the US is estimated to be greater than 
4–5% of those over 75 years of age. Approximately 50% of all US 
patients and over 75% of those over 80 years of age having clinical 
indications for surgical aortic valve replacement (AVR) are not 
being surgically treated due to either the lack of referral by clini-
cians or patient/family refusal. The use of TAVR has been projected 
to make substantial inroads in this underserved population, particu-
larly those who are very elderly or deemed at high surgical risk.
The key randomized clinical trials (RCTs) PARTNER A & B 
(utilizing Edwards’ Sapien balloon expandable AVR) along with the 
CoreValve (Medtronic’s self-expanding percutaneous AVR) study 
of high-risk patients conclusively demonstrated improved long-
term patient survival employing TAVR compared to sAVR (standard 
surgical AVR) with acceptable stroke and bleeding rates for patients 
felt either surgically inoperable or at very high surgical risk. The 
median age of TAVR implantation in these study cohorts was 
approximately 84 years22,23.
TAVR had been available for clinical use in over 31 countries prior 
to United States FDA approval in 2011. To help ensure a rational 
diffusion of TAVR’s innovative technology partnerships between 
the Food and Drug Administration (FDA), the Center for Medicare 
and Medical Services (CMS) along with cardiovascular professional 
societies led by the American College of Cardiology (ACC) and 
the Society for Thoracic Surgery (STS) collaborated in the creation 
of critical Post Approval Studies, CMS Coverage Determination 
Criteria, a multi-societal competency document for institutional 
and professional utilization of TAVR technology accompanied 
by an expert consensus document and clinical practice guidelines 
for TAVR clinical use. STS and ACC have created the STS/ACC 
transcatheter valve therapy (TVT) Registry where all commercial 
TAVR implants are required to be enrolled by hospitals to satisfy 
CMS coverage and payment requirements24–27. As of spring 2015, 
over 30,000 TAVR patients from approximately 350 institutions 
have been entered into the TVT Registry.
The TVT Registry data has been instrumental in assuring quality 
of care along with providing the infrastructure for performing Post 
Approval Studies, Investigational Device Exemption Studies, and 
Post Market Surveillance28,29. The Registry allowed earlier FDA 
approval than would be possible through previous RCT mechanisms 
for “Valve-in-Valve” TAVR use and also for alternative access use 
in high-risk and surgically inoperable patients. The TVT Registry 
demonstrated 7.0% 30-day mortality, and 23.7% 1-year mortality 
with a stroke rate of 4.1%30.
Of great importance for assessing clinical decision-making for eld-
erly patients with AS, the TVT Registry is collecting both baseline 
and longitudinal data on frailty and activity limitation assessments 
through 5-meter walk tests and the Kansas City Cardiomyopathy 
Questionnaire (KCCQ). In addition, the TVT Registry is creating 
a risk-adjusted mortality model that will hopefully soon be trans-
formed into a predictive outcome tool to help clinicians, patients, 
and families make informed decisions in the management of elderly 
and very elderly patients with AS.
Atrial fibrillation
The median age of patients with AF is 75 years, with a preva-
lence of about 9% in the elderly31. Stroke stands out as one of the 
greatest risks attributable to this arrhythmia. The 2014 American 
Heart Association/ACC/Heart Rhythm Society (AHA/ACC/HRS) 
guideline32 recommends using the CHA2DS2-VASc (Congestive HF 
[CHF], Hypertension, Age ≥75 years, Diabetes, Stroke/Transient 
ischemic attack [TIA], Vascular disease, Age 65–74, Sex category 
[female]) score to assess stroke risk. The guideline recommends oral 
anticoagulant therapy for AF patients with a CHA2DS2-VASc >2 
using warfarin or one of the new oral anticoagulants (NOACs) 
dabigatran, rivaroxaban, or apixaban. Edoxaban is another NOAC 
that was approved for use after the guideline was published, but it 
has efficacy that is comparable to those approved earlier.
Page 4 of 9
F1000Research 2016, 5(F1000 Faculty Rev):112 Last updated: 16 FEB 2016
As age >75 years leads to a minimum CHA2DS2-VASc score of 2, 
many emphasize the value of anticoagulation for most elderly 
patients with AF and decry the underuse of such vital therapy. 
Nonetheless, this still remains an issue of debate amidst age-related 
intricacies of care, i.e. intrinsic bleeding risks are often compounded 
by frailty, multimorbidity, polypharmacy, falls, and other manage-
ment complexities.
There have been several studies to estimate the risk/benefit ratio 
of treating elderly AF patients with oral anticoagulation, including 
the Birmingham Atrial Fibrillation Treatment of the Aged (BAFTA) 
study33, which randomized individuals aged ≥75 years of age to 
aspirin or warfarin based on physician discretion. Stroke/systemic 
embolism (SE) occurred at a rate of 1.8%/year in warfarin-treated 
patients versus 3.8%/year in the aspirin group (HR 0.48; 95% 
CI, 0.28–0.80), with no difference in the rates of major hemorrhage 
(1.9 vs. 2.2%, respectively). The risk for bleeding with warfarin 
therapy in patients >80 years of age has been estimated to range 
from 1.63% to 13.1% per year34,35.
The NOACs have generated much excitement in the field of AF 
management, as they enable relatively simplified treatment com-
pared to warfarin (e.g. reduced need for blood testing and no dietary 
restrictions). NOACs that include both direct thrombin inhibitors 
(dabigatran) and factor X inhibitors (rivaroxaban, apixaban, and 
edoxaban) are now available as alternatives to warfarin. All have 
been shown to be non-inferior to warfarin with respect to stroke and 
SE, with comparable rates of bleeding36–39. The mean age of patients 
in these studies was approximately 70 years, with about one-third 
of the patients being over 75 years.
A recent meta-analysis of the efficacy and harm of the NOACs for 
prevention of stroke in AF and secondary prevention of thromboem-
bolism found that the efficacy of each of the NOACs was equal or 
superior to warfarin in elderly patients40. Dabigatran was associated 
with a higher risk of gastrointestinal bleeding and a lower risk of 
intracranial bleeding. A significantly lower risk of major bleeding 
compared to warfarin was found for apixaban (odds ratio 0.63, 95% 
CI 0.51–0.77) and edoxaban 60 mg (0.81, 0.67–0.98) and 30 mg 
(0.46, 0.38–0.57), while rivaroxaban showed similar risks.
Amyloidosis
Cardiac amyloid has traditionally been considered a rare cardiovas-
cular condition. However, emerging data demonstrate that transthy-
retin cardiac amyloidosis (ATTR), formerly known as senile cardiac 
amyloidosis, caused by misfolded monomers or oligomers of the 
protein transthyretin (TTR), is a common cause of HFpEF. Indeed 
recent autopsy studies in HFpEF subjects (mean age 76 years) 
showed 21% had amyloid deposits and the prevalence was greater 
in those ≥75 years (32%) vs. <75 years (8%). Furthermore, only 
20% of the HFpEF patients with amyloid at autopsy had received a 
pre-morbid diagnosis41.
Bone isotopes, commonly used in bone scans, have a high sen-
sitivity and specificity (>90%) for identifying TTR cardiac amy-
loid due to either wild-type TTR or a mutant allele42,43. While over 
20 mutations can cause TTR cardiac amyloidosis, the Val122Ile 
mutation (substitution of isoleucine for valine at position 122) is 
the most common in the United States with a particularly high fre-
quency (prevalence of 3.4% to 3.9%) in African-Americans44. The 
Thr60Ala mutation (substitution of alanine for threonine at posi-
tion 60) is also notably common in individuals of Irish descent and 
is referred to as the Appalachian mutation. These genetic condi-
tions have an age-dependent penetrance, with males over the age of 
60 years being most commonly affected.
Historically, cardiac amyloid was difficult to diagnose because it can 
masquerade as other cardiovascular disorders45 and usually required 
endomyocardial biopsy. The diagnosis has become easier with the 
discovery that bone isotopes have a very high sensitivity and spe-
cificity for distinguishing ATTR cardiac amyloid (both mutant 
and wild-type) from light chain (AL) cardiac amyloid46 and other 
types of cardiomyopathy that mimic amyloid (e.g. hypertrophic 
cardiomyopathy). Differentiating TTR from AL cardiac amyloid 
has important prognostic, management, counseling, and therapeutic 
implications. These nuclear medicine techniques have the potential 
to dramatically alter the outcomes of patients with ATTR cardiac 
amyloidosis, particularly because new therapeutic options are looming.
Emerging therapeutic strategies to treat ATTR amyloid are focused 
on small molecules to stabilize the transthyretin tetramer and 
agents to silence TTR production. Phase II clinical trial data47 sug-
gest that tafamidis was generally well tolerated and stabilized TTR, 
leading to a phase III clinical trial that has completed enrollment. 
TTR silencers using either small interfering RNA (siRNA) or oli-
gonucleotides specific for silencing TTR production have shown 
remarkable ability to lower TTR to >80% of normal levels in sub-
jects with TTR cardiac amyloidosis. Collectively, such data remind 
us that TTR cardiac amyloid is certainly not rare and hopefully not 
unmodifiable.
Preventive care
Recent guidelines for cardiovascular prevention importantly 
emphasize that older adults are at highest risk for atherosclerotic 
cardiovascular events. Paradoxically, however, strategies focused 
on cardiovascular prevention are often underutilized in this 
subpopulation48. As the elderly also have the greatest burden of 
comorbidities, polypharmacy, and potential for medication-related 
side effects, the need for comprehensive and collaborative clini-
cian-patient management is imperative49.
Potential overtreatment of hypertension, in addition to inadequate 
control, may cause adverse outcomes in the elderly, who are more 
likely to have target organ damage. Considerable debate has arisen 
from the guideline recommendations made by the panel members 
appointed to JNC 8 (Eighth Joint National Committee) that blood 
pressure should be reduced to less than 150/90 mm Hg in adults 
aged 60 years and older without diabetes or chronic kidney disease50. 
In support of the ACC/AHA 2011 Expert Consensus document on 
hypertension in the elderly51 that recommended blood pressure be 
reduced to less than 140/90 in adults aged 60–79 (and a systolic 
pressure of 140–145 if tolerated in adults aged 80 and older) are data 
from REGARDS (REasons for Geographic and Racial Differences 
in Stroke), which reported that optimal blood pressure for elderly 
patients on antihypertensive therapy for the reduction of cardiovas-
cular events and all-cause mortality was less than 140/90 mm Hg52.
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Several recommended caveats for the care of older adults are high-
lighted by the ACC/AHA 2013 guidelines for the treatment of 
blood cholesterol, including the use of moderate-intensity statin 
therapy in adults >75 years of age with established atherosclerotic 
CVD (ASCVD). The ASCVD pooled cohort risk estimator does 
not provide for risk assessment in patients >79 years of age53. When 
initiating statin therapy, the risk of transitioning to diabetes should 
be discussed, although this risk is small in relation to the potential 
benefits of statin medications. Importantly, there is no definitive 
evidence that statins lead to cognitive decline. The available 
data on the use of proprotein convertase subtilisin/kexin type 
9 (PCSK9) inhibitor therapy in those of advanced age is promising, 
as low-density lipoprotein (LDL)-C is potently reduced with a side 
effect profile similar to that of placebo54.
Lifestyle approaches remain the cornerstone for cardiovascular pre-
vention in the elderly. Among persons aged 55 to 80 (mean age 67) 
at increased cardiovascular risk, a Mediterranean diet supplemented 
with extra-virgin olive oil or mixed nuts reduced the incidence of 
major cardiovascular events by 30%55. Emphasizing a goal of liv-
ing longer and better, a Mediterranean lifestyle including dietary 
pattern, moderate alcohol intake, regular physical activity, and not 
smoking was associated with a 60% reduction in all-cause mortality 
in elderly Europeans aged 70–9056.
The value of geriatric measures in patient-centered 
decision-making for clinical cardiovascular problems
In general, medications, procedures, and other components of car-
diovascular care are more likely to entail trade-offs at elderly age. 
Polypharmacy, pain, fatigue, confusion, dysgeusia, excessive time 
for recovery, and other sequelae may detract from (and sometimes 
even supersede) intended therapeutic benefits57,58. Whereas life 
prolongation is the overriding goal of therapy in the young, for 
many seniors issues of independence, quality of life, and functional 
capacity are often more important, and this may determine thera-
peutic choices that contrast with those of younger populations. This 
broader spectrum of clinical objectives and the high susceptibility 
to iatrogenesis are driving rationales for a growing emphasis on 
principles of shared decision-making between older patients and 
their clinicians57,58.
Other age-related issues that commonly affect caregiving of older 
cardiac patients include frailty, altered body composition (diminished 
lean body mass and increased interstitial fat), and changes in 
cognition. Frailty is often assessed as a constellation of phenotypic 
changes that relate to a state of increased vulnerability, i.e. slowing, 
weakening, weight loss, exhaustion, and reduced activity59. Patients 
with three or more of these measures are considered frail and are 
generally at increased risk for disease but also for poor tolerance 
of therapy. Frailty therefore fundamentally factors into therapeutic 
decisions and management strategies. Sarcopenia or reduced lean 
body mass is a subpart of frailty and directly detracts from physi-
cal capacity and vital resiliency to recover60. Diminished cognition, 
particularly executive function, is similarly insidious and detrimental, 
and complicating with regard to decision-making and adherence, 
and even in respect to the quality of life benefits that are achievable 
by therapy61.
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